# Daiichi Sankyo (4568) Q1 FY2026 earnings

Results filed 2026-07-31 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/daiichi-sankyo/2026-q1/
Press release and documents: https://www.daiichisankyo.com/investors/library/quarterly_result/
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Enhertu won two early-breast-cancer approvals in the US and Datroway added first-line triple-negative breast cancer, widening the DXd antibody drug conjugate franchise.

Daiichi Sankyo's growth came from its two main cancer drugs, Enhertu and Datroway. In May the US approved Enhertu before and after surgery for HER2 positive early breast cancer, and Datroway as first-line treatment for triple-negative breast cancer. Europe approved Enhertu for HER2 positive solid tumors in June. Datroway has now treated approx. 7,000 patients globally, about 1.4 times the prior quarter.
Management is concentrating resources on five DXd antibody drug conjugates (ADCs) and aims to find new core technologies by fiscal 2030. Next milestones include a US decision on ifinatamab deruxtecan in small cell lung cancer (PDUFA date Oct 10, 2026) and several late-stage Datroway readouts. The tension is that profit-sharing with AstraZeneca rises with Enhertu sales, and the company is restructuring its EU specialty business.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue | JPY574.7 billion | up 21.1% year on year | GAAP |
| Operating profit | JPY85.1 billion | down 12.0% year on year | GAAP |
| Profit attributable to owners of the Company | JPY68.6 billion | down 19.7% year on year | GAAP |
| Diluted EPS (JPY) | 37.70 | from 46.01 a year ago | GAAP |
| Core operating profit | JPY107.3 billion | up 6.2% year on year | non-GAAP |
| Free cash flow (JPY billions) | 48.8 | from -37.4 a year ago |  |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Oncology Business Unit | JPY197.4 billion | up 50.5% year on year |
| Japan Business Unit | JPY120.0 billion | down 3.9% year on year |
| EU Specialty Business Unit | JPY74.7 billion | up 17.1% year on year |
| ASCA Business Unit | JPY68.7 billion | up 21.0% year on year |
| American Regent Unit | JPY42.2 billion | down 14.3% year on year |
| Daiichi Sankyo Healthcare Unit | JPY22.6 billion | up 7.9% year on year |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Revenue | fiscal year ending March 31, 2027 | JPY2,340.0 billion |
| Operating profit | fiscal year ending March 31, 2027 | JPY320.0 billion |
| Capital expenditure (JPY billions) | FY2026 | 200.0 |

## Key takeaways

1. **Enhertu now covers early-stage through metastatic breast cancer** Two US approvals in May 2026, neoadjuvant and adjuvant, let Enhertu be used from early-stage to metastatic disease. Enhertu sales growth is also led by HER2 positive solid tumors in the US, and Europe approved that tumor-agnostic indication in June.
2. **Datroway adds first-line triple-negative breast cancer** US approval came in May 2026 for patients not eligible for PD-1/PD-L1 therapy, with new patient starts rising since. Together Enhertu and Datroway can now treat over 90% of metastatic breast cancer patients, based on molecular subtypes.
3. **Datroway uptake is accelerating** Approx. 7,000 patients have been treated globally, about 1.4 times the prior quarter. US sales are mainly driven by lung cancer, and the company maintained the No. 1 patient share in 3L+ EGFR-mutated NSCLC.
4. **Pipeline decisions cluster around the next two quarters** The US review of ifinatamab deruxtecan in extensive-stage small cell lung cancer has a PDUFA date of Oct 10, 2026. Several Phase 3 Datroway readouts and an EU decision on Enhertu with pertuzumab are also expected.
5. **Alliances and restructuring shape the profit picture** Higher profit-sharing with AstraZeneca on Enhertu weighs on selling costs, and the EU Specialty Business Unit is being reorganized. The company also agreed to sell its healthcare unit to Suntory in stages, with 30% transferred on July 1, 2026.

## Questions

**What new approvals did Enhertu receive this quarter?** In May 2026 the US approved Enhertu for neoadjuvant and adjuvant treatment of HER2 positive early breast cancer. In June 2026 Europe approved it for unresectable or metastatic HER2 positive (IHC3+) solid tumors.
**How is Datroway being adopted?** Datroway has treated approx. 7,000 patients globally, about 1.4 times the prior quarter. US sales are mainly driven by lung cancer, and triple-negative breast cancer is growing steadily after its May 2026 US approval.
**What is the next major regulatory event for the pipeline?** The US decision on ifinatamab deruxtecan for extensive-stage small cell lung cancer, which has priority review and a PDUFA date of Oct 10, 2026. An EU decision on Datroway in triple-negative breast cancer is also expected in the first half of FY2026.
**Where is management steering R&D?** It is concentrating resources on five DXd ADCs and aims to identify next Breakthrough Generating Technologies by fiscal 2030. New programs include DS1025 (a Treg-directed ADC) and a planned Datroway plus rilvegostomig Phase 3 in muscle-invasive urothelial carcinoma.
**What are the main business risks in the plan?** Profit sharing with AstraZeneca grows as Enhertu sales rise, offsetting part of the revenue gain in core operating profit guidance. American Regent revenue fell 14.3% on lower Venofer and Injectafer sales, and the EU Specialty unit is being restructured.

## Slides and investor documents

- [FY2026 Q1 Financial Results Presentation Material](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2026/FY2026Q1_Financial_Results_Presentation_E.pdf) (Slide deck)

